Pasquale Lombardi retweetledi

Proud of @paslombardi for his efforts in addressing unmet needs in 2L therapy for HCC
HCC CONNECT powered by COR2ED@hccconnectinfo
LEVIATHAN publication Get expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for #HCC 📺 from Prof. David Pinato (@DJPinato) 🤝 Programme endorsed by @EuropeLiver, @BlueFaeryLiver, @GlobalLiver & @ESDO_tweets View/download the infographic: cor2ed.com/hcc-connect/pr… This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content. #MedEd #Oncology
English






























